FibroGen, Inc. Reports Data From Phase 2 Hemoglobin Correction Study of Roxadustat (FG-4592) in Chinese Patients With Chronic Kidney Disease

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

Help employers find you! Check out all the jobs and post your resume.

Back to news